For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250321:nRSU5784Ba&default-theme=true
RNS Number : 5784B Haleon PLC 21 March 2025
Haleon plc: Publication of Annual Report and Form 20-F 2024
21 March 2025: Haleon plc (the "Company") has published its Annual Report and
Form 20-F for the year ended 31 December 2024 (the "Annual Report").
The Annual Report has been submitted to the National Storage Mechanism and is
available for inspection at data.fca.org.uk/#/nsm/nationalstoragemechanism
(http://data.fca.org.uk/#/nsm/nationalstoragemechanism) .
The Company has filed the Annual Report with the US Securities and Exchange
Commission.
The Annual Report is publicly available on the Company's website at
http://www.haleon.com/investors/annual-report-2024
(http://www.haleon.com/investors/annual-report-2024) .
In compliance with the Disclosure Guidance and Transparency Rules, the Annual
Report, as submitted to the National Storage Mechanism, contains regulated
information in unedited full text and is available on the Company's website as
noted above.
Shareholders may request a hard copy of the Annual Report, including the
complete audited financial statements of the Company. Requests should be
directed to: Company Secretariat, Haleon plc, Building 5, First Floor, The
Heights, Weybridge, KT13 0NY, United Kingdom or to
corporate.secretariat@haleon.com (mailto:corporate.secretariat@haleon.com) .
The Company's Annual General Meeting ("AGM") will take place on 28 May 2025.
The Notice of AGM will be published and distributed to shareholders in due
course.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com (http://www.haleon.com/)
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ACSMZGZFGGZGKZZ